Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesothelin-Specific CAR T Cells in Metastatic Breast Cancer
NCT02792114Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2016
- Primary completion
- Jun 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IcasM28z in breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Jun 2016; status: active, not recruiting.
02
Drugs
IcasM28z
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02792114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02792114.